New-Onset Mental Health Issue After Cancer Diagnosis Tied to Higher Risk for Death
Medically reviewed by Drugs.com
via HealthDayFRIDAY, Feb. 27, 2026 -- Adult patients with cancer who experience a new-onset mental health disorder (MHD) have an increased risk for death, according to a study published online Feb. 23 in Cancer.
Amir Ashraf Ganjouei, M.D., from University of California San Francisco (UCSF), and colleagues assessed patterns in the emergence of new MHDs within the first year following a cancer diagnosis. The analysis included aggregated data of 371,897 adult patients seen at University of California-affiliated hospitals with a cancer diagnosis and no documented MHDs before cancer diagnosis between 2013 and 2023.
The researchers found that following an incident cancer diagnosis, 10.6 percent of patients developed a new MHD within a year. Of these, 35.0 percent were newly prescribed one or more oral psychotropic medications. In an adjusted analysis, early MHD was associated with increased all-cause mortality in the initial 12 through 35 months (hazard ratio [HR], 1.51; 95 percent confidence interval [CI], 1.47 to 1.56). This risk diminished at 36 through 59 months (HR, 1.17; 95 percent CI, 1.11 to 1.24) and at 60 through 120 months (HR, 0.95; 95 percent CI, 0.89 to 1.01).
"Over the past several years, we’ve had an increasing appreciation for the important relationship between cancer, its treatment, and mental health," lead author Julian Hong, M.D., also from UCSF, said in a statement. "This study reproduces our prior work by leveraging the shared experience across the University of California system, reinforcing a relationship between mental health conditions and mortality for patients with cancer and highlighting the need to prioritize and manage mental health."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-01 01:29
Read more
- Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
- CagriSema Demonstrated 23% Weight Loss in an Open-Label Head-to-Head REDEFINE 4 Trial in People with Obesity, the Primary Endpoint Was Not Achieved
- Flea And Tick Pills May Pose Environmental Risks, Study Finds
- Scientists' Push For a Universal Vaccine Takes a Key Step Forward
- Frozen Blueberry Recall Issued Across Four States for Listeria
- Novartis Remibrutinib First Therapy to Achieve Phase III Primary Endpoint in Chronic Inducible Urticaria (CIndU)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions